An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969 · see citing works

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286 · see citing works

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897 · see citing works

Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein

Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586 · see citing works

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923 · see citing works

Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus

Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020) · Journal of Virology · doi:10.1128/jvi.00127-20 · Cited by 4,341 · see citing works

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281 · see citing works

Structural basis of receptor recognition by SARS-CoV-2

Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661 · see citing works

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109 · see citing works

Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses

Su, S., Wong, G., Shi, W., Liu, J., Lai, A. C.-K., Zhou, J., Liu, W., Bi, Y., & Gao, G. F. (2016) · Trends in Microbiology · doi:10.1016/j.tim.2016.03.003 · Cited by 2,956 · see citing works

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

Monteil, V., Kwon, H., Prado, P., Hagelkrüys, A., Wimmer, R. A., Stahl, M., Leopoldi, A., Garreta, E., Hurtado del Pozo, C., Prosper, F., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.004 · Cited by 2,122 · see citing works

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

Starr, T. N., Greaney, A. J., Hilton, S. K., Ellis, D., Crawford, K. H. D., Dingens, A. S., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.012 · Cited by 1,956 · see citing works

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885 · see citing works

Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data

Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., O’Toole, Á., et al. (2021) · doi:10.1101/2020.12.30.20249034 · Cited by 1,611 · see citing works

Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England

The COVID-19 Genomics UK (COG-UK) consortium, Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., et al. (2021) · Nature · doi:10.1038/s41586-021-03470-x · Cited by 1,611 · see citing works

SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity

Zhang, L., Jackson, C. B., Mou, H., Ojha, A., Peng, H., Quinlan, B. D., Rangarajan, E. S., Pan, A., Vanderheiden, A., Suthar, M. S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19808-4 · Cited by 1,387 · see citing works

Deep mutational scanning: a new style of protein science

Fowler, D. M., & Fields, S. (2014) · Nature Methods · doi:10.1038/nmeth.3027 · Cited by 1,287 · see citing works

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Baum, A., Fulton, B. O., Wloga, E., Copin, R., Pascal, K. E., Russo, V., Giordano, S., Lanza, K., Negron, N., Ni, M., et al. (2020) · Science · doi:10.1126/science.abd0831 · Cited by 1,253 · see citing works

Distinct conformational states of SARS-CoV-2 spike protein

Cai, Y., Zhang, J., Xiao, T., Peng, H., Sterling, S. M., Walsh, R. M., Rawson, S., Rits-Volloch, S., & Chen, B. (2020) · Science · doi:10.1126/science.abd4251 · Cited by 1,221 · see citing works

Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans

Munnink, B. B. O., Sikkema, R. S., Nieuwenhuijse, D. F., Molenaar, R. J., Münger, E., Molenkamp, R., van der Spek, A. N., Tolsma, P., Rietveld, A., Brouwer, M., et al. (2020) · Science · doi:10.1126/science.abe5901 · Cited by 1,087 · see citing works

Molecular Architecture of the SARS-CoV-2 Virus

Yao, H., Song, Y., Chen, Y., Wu, N., Xu, J., Sun, C., Zhang, J., Weng, T., Zhang, Z., Wu, Z., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.018 · Cited by 1,060 · see citing works

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

Greaney, A. J., Starr, T. N., Gilchuk, P., Zost, S. J., Binshtein, E., Loes, A. N., Hilton, S. K., Huddleston, J., Eguia, R., Crawford, K. H. D., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2020.11.007 · Cited by 1,016 · see citing works

Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic

Boni, M. F., Lemey, P., Jiang, X., Lam, T. T.-Y., Perry, B. W., Castoe, T. A., Rambaut, A., & Robertson, D. L. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0771-4 · Cited by 1,014 · see citing works

Receptor and viral determinants of SARS‐coronavirus adaptation to human ACE2

Li, W., Zhang, C., Sui, J., Kuhn, J. H., Moore, M. J., Luo, S., Wong, S.-K., Huang, I., Xu, K., Vasilieva, N. Y., et al. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600640 · Cited by 976 · see citing works

Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognitionPreprint

Greaney, A. J., Starr, T. N., Gilchuk, P., Zost, S. J., Binshtein, E., Loes, A. N., Hilton, S. K., Huddleston, J., Eguia, R. T., Crawford, K. H. D., et al. (2020) · bioRxiv · doi:10.1101/2020.09.10.292078 · Cited by 948 · see citing works

De novo design of picomolar SARS-CoV-2 miniprotein inhibitors

Cao, L., Goreshnik, I., Coventry, B., Case, J. B., Miller, L., Kozodoy, L., Chen, R. E., Carter, L., Walls, A. C., Park, Y.-J., et al. (2020) · Science · doi:10.1126/science.abd9909 · Cited by 742 · see citing works

Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2

Chan, K. K., Dorosky, D. E., Sharma, P. A., Abbasi, S. A., Dye, J. M., Kranz, D. M., Herbert, A. S., & Procko, E. (2020) · Science · doi:10.1126/science.abc0870 · Cited by 613 · see citing works

The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivityPreprint

Zhang, L., Jackson, C. B., Mou, H., et al. (2020) · bioRxiv · doi:10.1101/2020.06.12.148726 · Cited by 576 · see citing works

Evolution and epidemic spread of SARS-CoV-2 in Brazil

Candido, D. S., Claro, I. M., de Jesus, J. G., Souza, W. M., Moreira, F. R. R., Dellicour, S., Mellan, T. A., du Plessis, L., Pereira, R. H. M., Sales, F. C. S., et al. (2020) · Science · doi:10.1126/science.abd2161 · Cited by 573 · see citing works

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

Tortorici, M. A., Beltramello, M., Lempp, F. A., Pinto, D., Dang, H. V., Rosen, L. E., McCallum, M., Bowen, J., Minola, A., Jaconi, S., et al. (2020) · Science · doi:10.1126/science.abe3354 · Cited by 510 · see citing works

Global analysis of protein folding using massively parallel design, synthesis, and testing

Rocklin, G. J., Chidyausiku, T. M., Goreshnik, I., Ford, A., Houliston, S., Lemak, A., Carter, L., Ravichandran, R., Mulligan, V. K., Chevalier, A., et al. (2017) · Science · doi:10.1126/science.aan0693 · Cited by 501 · see citing works

Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis

Kirchdoerfer, R. N., Wang, N., Pallesen, J., Wrapp, D., Turner, H. L., Cottrell, C. A., Corbett, K. S., Graham, B. S., McLellan, J. S., & Ward, A. B. (2018) · Scientific Reports · doi:10.1038/s41598-018-34171-7 · Cited by 466 · see citing works

Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig

Lei, C., Qian, K., Tian, L., Zhang, S., Fu, W., Ding, M., & Hu, S. (2020) · Nature Communications · doi:10.1038/s41467-020-16048-4 · Cited by 450 · see citing works

Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia

Sabir, J. S. M., Lam, T. T., Ahmed, M. M. M., Li, L., Shen, Y., Abo‐Aba, S. E. M., Qureshi, M. I., Abu-Zeid, M., Zhang, Y., Khiyami, M. A., et al. (2015) · Science · doi:10.1126/science.aac8608 · Cited by 442 · see citing works

Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets

Jiang, F., Yang, J., Zhang, Y., Dong, M., Wang, S., Zhang, Q., Liu, F., Zhang, K., & Zhang, C. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.59 · Cited by 427 · see citing works

Controlling the SARS-CoV-2 spike glycoprotein conformation

Henderson, R. C., Edwards, R. J., Mansouri, K., Janowska, K., Stalls, V., Gobeil, S., Kopp, M., Li, D., Parks, R., Hsu, A. L., et al. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0479-4 · Cited by 410 · see citing works

Human recombinant soluble ACE2 in severe COVID-19

Zoufaly, A., Poglitsch, M., Aberle, J. H., Hoepler, W., Seitz, T., Traugott, M. T., Grieb, A., Pawelka, E., Laferl, H., Wenisch, C., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30418-5 · Cited by 402 · see citing works

Emergence of SARS-CoV-2 through recombination and strong purifying selection

Li, X., Giorgi, E. E., Marichannegowda, M. H., Foley, B. T., Xiao, C., Kong, X., Chen, Y., Gnanakaran, S., Korber, B., & Gao, F. (2020) · Science Advances · doi:10.1126/sciadv.abb9153 · Cited by 392 · see citing works

ACE2, Much More Than Just a Receptor for SARS-COV-2

Samavati, L., & Uhal, B. D. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00317 · Cited by 366 · see citing works

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges

Gardner, M. R., Kattenhorn, L. M., Kondur, H. R., von Schaewen, M., Dorfman, T., Chiang, J. J., Haworth, K. G., Decker, J. M., Alpert, M. D., Bailey, C. C., et al. (2015) · Nature · doi:10.1038/nature14264 · Cited by 299 · see citing works

Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor

Hofmann, H., Geier, M., Marzi, A., Krumbiegel, M., Peipp, M., Fey, G. H., Gramberg, T., & Pöhlmann, S. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.05.114 · Cited by 254 · see citing works

Engineered ACE2 receptor traps potently neutralize SARS-CoV-2

Glasgow, A., Glasgow, J., Limonta, D., Solomon, P., Lui, I., Zhang, Y., Nix, M. A., Rettko, N. J., Zha, S., Yamin, R., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2016093117 · Cited by 251 · see citing works

Mechanisms of Host Receptor Adaptation by Severe Acute Respiratory Syndrome Coronavirus

Wu, K., Peng, G., Wilken, M. S., Geraghty, R. J., & Li, F. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.325803 · Cited by 246 · see citing works

De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2

Linsky, T. W., Vergara, R., Codina, N., Nelson, J. W., Walker, M. J., Su, W., Barnes, C. O., Hsiang, T.-Y., Esser-Nobis, K., Yu, K., et al. (2020) · Science · doi:10.1126/science.abe0075 · Cited by 216 · see citing works

Enrich: software for analysis of protein function by enrichment and depletion of variants

Fowler, D. M., Araya, C. L., Gerard, W., & Fields, S. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr577 · Cited by 121 · see citing works

Publisher Correction: Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis

Kirchdoerfer, R. N., Wang, N., Pallesen, J., Wrapp, D., Turner, H. L., Cottrell, C. A., Corbett, K. S., Graham, B. S., McLellan, J. S., & Ward, A. B. (2018) · Scientific Reports · doi:10.1038/s41598-018-36918-8 · Cited by 98 · see citing works

Computational Design of a Protein-Based Enzyme Inhibitor

Procko, E., Hedman, R., Hamilton, K., Seetharaman, J., Fleishman, S. J., Su, M., Aramini, J. M., Kornhaber, G. J., Hunt, J. F., Tong, L., et al. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.06.035 · Cited by 88 · see citing works

Mapping Interaction Sites on Human Chemokine Receptors by Deep Mutational Scanning

Heredia, J. D., Park, J., Brubaker, R. J., Szymanski, S. K., Gill, K. S., & Procko, E. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800343 · Cited by 65 · see citing works

Structural architecture of a dimeric class C GPCR based on co-trafficking of sweet taste receptor subunits

Park, J., Selvam, B., Sanematsu, K., Shigemura, N., Shukla, D., & Procko, E. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006173 · Cited by 59 · see citing works

Exceptional diversity and selection pressure on coronavirus host receptors in bats compared to other mammals

Frank, H. K., Enard, D., & Boyd, S. D. (2022) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2022.0193 · Cited by 51 · see citing works

Exceptional diversity and selection pressure on SARS-CoV and SARS-CoV-2 host receptor in bats compared to other mammalsPreprint

Frank, H. K., Enard, D., & Boyd, S. D. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.20.051656 · Cited by 41 · see citing works

eCD4-Ig Limits HIV-1 Escape More Effectively than CD4-Ig or a Broadly Neutralizing Antibody

Fellinger, C. H., Gardner, M. R., Weber, J. A., Alfant, B., Zhou, A. S., & Farzan, M. (2019) · Journal of Virology · doi:10.1128/jvi.00443-19 · Cited by 27 · see citing works

Massive dissemination of a SARS-CoV-2 Spike Y839 variant in Portugal

Borges, V., Isidro, J., Martins, H. C., Duarte, S., Mota‐Vieira, L., Leite, R. B., Gordo, I., Caetano, C., Nunes, B., Sá, R., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1844552 · Cited by 26 · see citing works

High affinity modified ACE2 receptors protect from SARS-CoV-2 infection in hamstersPreprint

Higuchi, Y., Suzuki, T., Arimori, T., Ikemura, N., Mihara, E., Kirita, Y., Ohgitani, E., Mazda, O., Motooka, D., Nakamura, S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.16.299891 · Cited by 18 · see citing works

On the track of the D839Y mutation in the SARS-CoV-2 Spike fusion peptide: emergence and geotemporal spread of a highly prevalent variant in PortugalPreprint

Borges, V., Isidro, J., Cortes-Martins, H., et al. (2020) · medRxiv · doi:10.1101/2020.08.10.20171884 · Cited by 5 · see citing works

Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England

The COVID-19 Genomics UK (COG-UK) consortium, Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., et al. (2021) · Nature · doi:10.1038/s41586-021-03470-x · Cited by 1,611 · see citing works

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Xie, X., Liu, Y., Liu, J., Zhang, X., Zou, J., Fontes-Garfias, C. R., Xia, H., Swanson, K. A., Cutler, M., Cooper, D., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01270-4 · Cited by 628 · see citing works

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Stamatatos, L., Czartoski, J., Wan, Y.-H., Homad, L. J., Rubin, V., Glantz, H., Neradilek, M., Seydoux, E., Jennewein, M. F., MacCamy, A. J., et al. (2021) · Science · doi:10.1126/science.abg9175 · Cited by 557 · see citing works

Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution

Starr, T. N., Greaney, A. J., Hannon, W. W., Loes, A. N., Hauser, K., Dillen, J., Ferri, E., Farrell, A. G., Dadonaite, B., McCallum, M., et al. (2022) · bioRxiv · doi:10.1126/science.abo7896 · Cited by 282 · see citing works

Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species

Wang, R., Zhang, Q., Ge, J., Ren, W., Zhang, R., Lan, J., Ju, B., Su, B., Yu, F., Chen, P., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.06.003 · Cited by 240 · see citing works

Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection

Hwang, Y., Lu, R., Su, S.-C., Chiang, P.-Y., Ko, S.-H., Ke, F.-Y., Liang, K.-H., Hsieh, T.-Y., & Wu, H. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-021-00784-w · Cited by 236 · see citing works

Learning from prepandemic data to forecast viral escape

Thadani, N. N., Gurev, S. F., Notin, P., Youssef, N., Rollins, N. J., Ritter, D., Sander, C., Gal, Y., & Marks, D. S. (2023) · Nature · doi:10.1038/s41586-023-06617-0 · Cited by 212 · see citing works

Deep mutational scans for ACE2 binding, RBD expression, and antibody escape in the SARS-CoV-2 Omicron BA.1 and BA.2 receptor-binding domains

Starr, T. N., Greaney, A. J., Stewart, C., Walls, A. C., Hannon, W. W., Veesler, D., & Bloom, J. D. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010951 · Cited by 196 · see citing works

A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses

Tauzin, A., Nayrac, M., Benlarbi, M., Gong, S. Y., Gasser, R., Beaudoin-Bussières, G., Brassard, N., Laumaea, A., Vézina, D., Prévost, J., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.001 · Cited by 187 · see citing works

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera

Xie, X., Zou, J., Fontes-Garfias, C. R., Xia, H., Swanson, K. A., Cutler, M., Cooper, D., Menachery, V. D., Weaver, S., Dormitzer, P. R., et al. (2021) · doi:10.1101/2021.01.07.425740 · Cited by 143 · see citing works

Nanotechnology-based strategies against SARS-CoV-2 variants

Huang, X., Kon, E., Han, X., Zhang, X., Kong, N., Mitchell, M. J., Peer, D., & Tao, W. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01174-5 · Cited by 143 · see citing works

Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies

Zabidi, N. Z., Liew, H. L., Farouk, I. A., Puniyamurti, A., Yip, A. J. W., Wijesinghe, V. N., Low, Z. Y., Tang, J. W.-T., Chow, V. T. K., & Lal, S. K. (2023) · Viruses · doi:10.3390/v15040944 · Cited by 121 · see citing works

Association between HLA genotypes and COVID-19 susceptibility, severity and progression: a comprehensive review of the literature

Migliorini, F., Torsiello, E., Spiezia, F., Oliva, F., Tingart, M., & Maffulli, N. (2021) · European journal of medical research · doi:10.1186/s40001-021-00563-1 · Cited by 114 · see citing works

SARS-CoV-2 evolution in animals suggests mechanisms for rapid variant selection

Bashor, L., Gagne, R. B., Bosco‐Lauth, A. M., Bowen, R. A., Stenglein, M. D., & VandeWoude, S. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2105253118 · Cited by 104 · see citing works

SARS-CoV-2 Antiviral Therapy

Tao, K., Tzou, P. L., Nouhin, J., Bonilla, H. F., Jagannathan, P., & Shafer, R. W. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00109-21 · Cited by 105 · see citing works

Engineered ACE2 decoy mitigates lung injury and death induced by SARS-CoV-2 variants

Zhang, L., Dutta, S., Xiong, S., Chan, M. C., Chan, K. K., Fan, T. M., Bailey, K. L., Lindeblad, M. O., Cooper, L. M., Rong, L., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-021-00965-6 · Cited by 85 · see citing works

Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion

Salleh, M. Z., Derrick, J. P., & Deris, Z. Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147425 · Cited by 79 · see citing works

ACE2 Shedding and the Role in COVID-19

Wang, J., Zhao, H., & An, Y. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.789180 · Cited by 78 · see citing works

ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker

Chen, Y., Zhang, Y., Yan, R., Wang, G., Zhang, Y., Zhang, Z., Li, Y., Ou, J., Chu, W., Liang, Z., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00740-y · Cited by 69 · see citing works

An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo

Ikemura, N., Taminishi, S., Inaba, T., Arimori, T., Motooka, D., Katoh, K., Kirita, Y., Higuchi, Y., Li, S., Suzuki, T., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn7737 · Cited by 61 · see citing works

Deep mutational scanning identifies SARS-CoV-2 Nucleocapsid escape mutations of currently available rapid antigen tests

Frank, F., Keen, M. M., Rao, A., Bassit, L., Liu, X., Bowers, H. B., Patel, A. B., Cato, M. L., Sullivan, J. A., Greenleaf, M. N., et al. (2022) · Cell · doi:10.1016/j.cell.2022.08.010 · Cited by 58 · see citing works

Rapid Increase of SARS-CoV-2 Variant B.1.1.7 Detected in Sewage Samples from England between October 2020 and January 2021

Wilton, T., Bujáki, E., Klapsa, D., Majumdar, M., Zambon, M. C. F. A., Fritzsche, M., Mate, R., & Martín, J. E.-S. (2021) · mSystems · doi:10.1128/msystems.00353-21 · Cited by 53 · see citing works

Advances in developing ACE2 derivatives against SARS-CoV-2

Zhang, H., Lv, P., Jiang, J., Liu, Y., Yan, R., Shu, S., Hu, B., Xiao, H., Cai, K., Yuan, S., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00011-3 · Cited by 55 · see citing works

Rapid characterization of spike variants via mammalian cell surface display

Javanmardi, K., Chou, C., Terrace, C. I., Annapareddy, A., Kaoud, T. S., Guo, Q., Lutgens, J., Zorkic, H., Horton, A. P., Gardner, E. C., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.11.024 · Cited by 51 · see citing works

Polarity‐Dominated Stable N97 Respirators for Airborne Virus Capture Based on Nanofibrous Membranes

Wang, Q., Wei, Y., Li, W., Luo, X., Zhang, X., Di, J., Wang, G., & Yu, J. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202108951 · Cited by 50 · see citing works

Protective neutralizing epitopes in SARS‐CoV‐2

Liu, H., & Wilson, I. A. (2022) · Immunological Reviews · doi:10.1111/imr.13084 · Cited by 46 · see citing works

An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS‐CoV‐2

Zhang, L., Narayanan, K. K., Cooper, L. M., Chan, K. K., Skeeters, S. S., Devlin, C. A., Aguhob, A., Shirley, K. M., Rong, L., Rehman, J., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202216109 · Cited by 50 · see citing works

Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities

Chen, Y., Sun, L., Ullah, I., Beaudoin-Bussières, G., Anand, S. P., Hederman, A. P., Tolbert, W. D., Sherburn, R. T., Nguyen, D. N. P., Marchitto, L., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn4188 · Cited by 48 · see citing works

RBD-specific polyclonal F(ab´)2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial

Lopardo, G. D., Belloso, W. H., Nannini, E. C., Colonna, M., Sanguineti, S., Zylberman, V., Muñoz, L., Dobarro, M., Lebersztein, G., Farina, J., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100843 · Cited by 47 · see citing works

Intranasal gene therapy to prevent infection by SARS-CoV-2 variants

Sims, J. J., Greig, J. A., Michalson, K. T., Lian, S., Martino, R. A., Meggersee, R., Turner, K. B., Nambiar, K., Dyer, C., Hinderer, C. J., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009544 · Cited by 42 · see citing works

Engineering ACE2 decoy receptors to combat viral escapability

Arimori, T., Ikemura, N., Okamoto, T., Takagi, J., Standley, D. M., & Hoshino, A. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.06.011 · Cited by 45 · see citing works

A Novel Soluble ACE2 Protein Provides Lung and Kidney Protection in Mice Susceptible to Lethal SARS-CoV-2 Infection

Hassler, L., Wysocki, J. A., Gelarden, I. A., Sharma, I., Τοματσίδου, Α., Ye, M., Gula, H., Nicoleascu, V., Randall, G. C., Pshenychnyi, S., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021091209 · Cited by 44 · see citing works

Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics

Chitsike, L., & Duerksen-Hughes, P. J. (2021) · Virology Journal · doi:10.1186/s12985-021-01624-x · Cited by 41 · see citing works

The past, current and future epidemiological dynamic of SARS-CoV-2

Balloux, F., Tan, C. C. S., Swadling, L., Richard, D., Jenner, C., Maini, M. K., & van Dorp, L. (2022) · Oxford Open Immunology · doi:10.1093/oxfimm/iqac003 · Cited by 37 · see citing works

A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responsesPreprint

Tauzin, A., Nayrac, M., Benlarbi, M., Gong, S. Y., Gasser, R., Beaudoin-Bussières, G., Brassard, N., Laumaea, A., Vézina, D., Prévost, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.18.435972 · Cited by 41 · see citing works

Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit

Hall, M. D., Anderson, J. M., Anderson, A. S., Baker, D. A., Bradner, J. E., Brimacombe, K. R., Campbell, E. A., Corbett, K. S., Carter, K. L., Cherry, S. R., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab305 · Cited by 40 · see citing works

The localized rise of a B.1.526 SARS-CoV-2 variant containing an E484K mutation in New York StatePreprint

Lasek‐Nesselquist, E., Lapierre, P., Schneider, E., George, K. S., & Pata, J. D. (2021) · medRxiv · doi:10.1101/2021.02.26.21251868 · Cited by 38 · see citing works

ACE2‐based decoy receptors for SARS coronavirus 2

Jing, W., & Procko, E. (2021) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26140 · Cited by 32 · see citing works

Exploring the Role of Glycans in the Interaction of SARS-CoV-2 RBD and Human Receptor ACE2

Nguyen, K., Chakraborty, S., Mansbach, R. A., Korber, B., & Gnanakaran, S. (2021) · Viruses · doi:10.3390/v13050927 · Cited by 36 · see citing works

Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy

Ridgway, H. F., Chasapis, C. T., Kelaidonis, K., Ligielli, I., Moore, G. J., Gadanec, L. K., Zulli, A., Apostolopoulos, V., Mavromoustakos, T., & Matsoukas, J. (2022) · Viruses · doi:10.3390/v14051029 · Cited by 35 · see citing works

CESSAT: A chemical additive-enhanced single-step accurate CRISPR/Cas13 testing system for field-deployable ultrasensitive detection and genotyping of SARS-CoV-2 variants of concern

Wang, Y., Chen, H., Gao, H., Wei, H., Wang, Y., Mu, K., Liu, L., Dai, E., Rong, Z., & Wang, S. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115238 · Cited by 34 · see citing works

The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity

Vaquero, S. T., de Campos‐Mata, L., Ramada, J. M., Díaz, P., Navarro‐Barriuso, J., Ribas‐Llauradó, C., Melero, N. R., Carolis, C., Cerutti, A., Gimeno, R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.737083 · Cited by 33 · see citing works

Computationally Designed ACE2 Decoy Receptor Binds SARS-CoV-2 Spike (S) Protein with Tight Nanomolar Affinity

Havranek, B., Chan, K. K., Wu, A., Procko, E., & Islam, S. M. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00783 · Cited by 32 · see citing works

Fast Prediction of Binding Affinities of the SARS-CoV-2 Spike Protein Mutant N501Y (UK Variant) with ACE2 and Miniprotein Drug Candidates

Williams, A. H., & Zhan, C. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c00869 · Cited by 31 · see citing works

ACE2, B0AT1, and SARS-CoV-2 spike protein: Structural and functional implications

Zhang, Y., Yan, R., & Zhou, Q. (2022) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2022.102388 · Cited by 31 · see citing works

AlphaFold2 Modeling and Molecular Dynamics Simulations of the Conformational Ensembles for the SARS-CoV-2 Spike Omicron JN.1, KP.2 and KP.3 Variants: Mutational Profiling of Binding Energetics Reveals Epistatic Drivers of the ACE2 Affinity and Escape Hotspots of Antibody Resistance

Raisinghani, N., Alshahrani, M., Gupta, G., & Verkhivker, G. M. (2024) · Viruses · doi:10.3390/v16091458 · Cited by 32 · see citing works

Decreased Interfacial Dynamics Caused by the N501Y Mutation in the SARS-CoV-2 S1 Spike:ACE2 Complex

Ahmed, W. S., Philip, A. M., & Biswas, K. H. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.846996 · Cited by 28 · see citing works

An engineered nano-liposome-human ACE2 decoy neutralizes SARS-CoV-2 Spike protein-induced inflammation in both murine and human macrophages

Satta, S., Meng, Z., Hernandez, R., Cavallero, S., Zhou, T., Hsiai, T. K., & Zhou, C. (2022) · Theranostics · doi:10.7150/thno.66831 · Cited by 27 · see citing works

Probing the biophysical constraints of SARS-CoV-2 spike N-terminal domain using deep mutational scanning

Ouyang, W. O., Tan, T. J. C., Lei, R., Song, G., Kieffer, C., Andrabi, R., Matreyek, K. A., & Wu, N. C. (2022) · Science Advances · doi:10.1126/sciadv.add7221 · Cited by 26 · see citing works

Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo

Torchia, J. A., Tavares, A. H., Carstensen, L. S., Chen, D. W., Huang, J., Xiao, T., Mukherjee, S., Reeves, P. M., Tu, H., Sluder, A. E., et al. (2022) · Science Advances · doi:10.1126/sciadv.abq6527 · Cited by 25 · see citing works

The first three waves of the Covid-19 pandemic hint at a limited genetic repertoire for SARS-CoV-2

Wassenaar, T. M., Wanchai, V., Buzard, G. S., & Ussery, D. W. (2022) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuac003 · Cited by 26 · see citing works

An overview of methods for the structural and functional mapping of epitopes recognized by anti-SARS-CoV-2 antibodies

Francino-Urdaniz, I., & Whitehead, T. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00169h · Cited by 20 · see citing works

The effects of amino acid substitution of spike protein and genomic recombination on the evolution of SARS-CoV-2

Fang, L., Xu, J., Zhao, Y., Fan, J., Shen, J., Liu, W., & Cao, G. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1228128 · Cited by 26 · see citing works

Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariants

Moriyama, S., Anraku, Y., Taminishi, S., Adachi, Y., Kuroda, D., Kita, S., Higuchi, Y., Kirita, Y., Kotaki, R., Tonouchi, K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39890-8 · Cited by 22 · see citing works

Analysis of IgM, IgA, and IgG isotype antibodies Directed against SARS-CoV-2 spike glycoprotein and ORF8 in the course of COVID-19

Meinberger, D., Koch, M., Roth, A., Hermes, G., Stemler, J., Cornely, O. A., Streichert, T., & Klatt, A. R. (2021) · Scientific Reports · doi:10.1038/s41598-021-88356-8 · Cited by 24 · see citing works

Generalized Methodology for the Quick Prediction of Variant SARS-CoV-2 Spike Protein Binding Affinities with Human Angiotensin-Converting Enzyme II

Williams, A. H., & Zhan, C. (2022) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c10718 · Cited by 24 · see citing works

Structure–Function Analysis of Resistance to Bamlanivimab by SARS-CoV-2 Variants Kappa, Delta, and Lambda

Liu, S., Huynh, T., Stauft, C. B., Wang, T. T., & Luan, B. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01058 · Cited by 22 · see citing works

Potential COVID‐19 therapeutic approaches targeting angiotensin‐converting enzyme 2; An updated review

Zanganeh, S., Goodarzi, N., Doroudian, M., & Movahed, E. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2321 · Cited by 23 · see citing works

Research progress in spike mutations of SARS‐CoV‐2 variants and vaccine development

He, X., He, C., Hong, W., Yang, H. J., & Wei, X. (2023) · Medicinal Research Reviews · doi:10.1002/med.21941 · Cited by 24 · see citing works

Computational decomposition reveals reshaping of the SARS‐CoV‐2–ACE2 interface among viral variants expressing the N501Y mutation

Socher, E., Conrad, M., Heger, L., Paulsen, F. P., Sticht, H., Zunke, F., & Arnold, P. (2021) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30142 · Cited by 22 · see citing works

A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants

Shan, S., Mok, C. K., Zhang, S., Lan, J., Li, J., Yang, Z., Wang, R., Cheng, L., Fang, M., Aw, Z. Q., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.766821 · Cited by 21 · see citing works

Whole-genome sequencing of SARS-CoV-2 in the Republic of Ireland during waves 1 and 2 of the pandemicPreprint

Mallon, P. W. G., Crispie, F., Gonzalez, G., Tinago, W., Léon, A., McCabe, M. S., de Barra, E., Yousif, O., Lambert, J. S., Walsh, C. J., et al. (2021) · medRxiv · doi:10.1101/2021.02.09.21251402 · Cited by 21 · see citing works

Comprehensive role of SARS‐CoV‐2 spike glycoprotein in regulating host signaling pathway

Banerjee, S., Wang, X., Du, S., Zhu, C., Jia, Y., Wang, Y., & Cai, Q. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27820 · Cited by 20 · see citing works

A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo

Havranek, B., Lindsey, G., Higuchi, Y., Itoh, Y., Suzuki, T., Okamoto, T., Hoshino, A., Procko, E., & Islam, S. M. (2023) · Communications Biology · doi:10.1038/s42003-023-04860-9 · Cited by 20 · see citing works

Deep Mutational Scanning of Viral Glycoproteins and Their Host Receptors

Narayanan, K. K., & Procko, E. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.636660 · Cited by 18 · see citing works

An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2Preprint

Zhang, L., Narayanan, K. K., Cooper, L. M., Chan, K. K., Devlin, C. A., Aguhob, A., Shirley, K. M., Rong, L., Rehman, J., Malik, A. B., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.28.486075 · Cited by 19 · see citing works

Next-generation treatments: Immunotherapy and advanced therapies for COVID-19

Arévalo-Romero, J. A., Chingaté-López, S. M., Camacho, B. A., Alméciga-Díaz, C., & Ramirez-Segura, C. A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26423 · Cited by 15 · see citing works

Multivalent ACE2 engineering—A promising pathway for advanced coronavirus nanomedicine development

Obeng, E. M., Fianu, I., & Danquah, M. K. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101580 · Cited by 17 · see citing works

Deep Mutational Scanning to Predict Escape from Bebtelovimab in SARS-CoV-2 Omicron Subvariants

Alcantara, M. C., Higuchi, Y., Kirita, Y., Matoba, S., & Hoshino, A. (2023) · Vaccines · doi:10.3390/vaccines11030711 · Cited by 17 · see citing works

Molecular insights and optimization strategies for the competitive binding of engineered ACE2 proteins: a multiple replica molecular dynamics study

Sun, J., Liu, X., Zhang, S., Li, M., Zhang, Q., & Chen, J. (2023) · Physical Chemistry Chemical Physics · doi:10.1039/d3cp03392a · Cited by 17 · see citing works

Predicting pathogen evolution and immune evasion in the age of artificial intelligence

Hamelin, D. J., Scicluna, M., Saadie, I., Mostefai, F., Grenier, J., Baron, C., Caron, É., & Hussin, J. (2025) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2025.03.044 · Cited by 17 · see citing works

Protein Scaffold‐Based Multimerization of Soluble ACE2 Efficiently Blocks SARS‐CoV‐2 Infection In Vitro and In Vivo

Kayabölen, A., Akcan, U., Özturan, D., Polat, H. Ü., Şahin, G. N., Degirmenci, N. P., Bayraktar, C., Söyler, G., Sarayloo, E., Nurtop, E., et al. (2022) · Advanced Science · doi:10.1002/advs.202201294 · Cited by 14 · see citing works

Deep mutagenesis scanning using whole trimeric SARS-CoV-2 spike highlights the importance of NTD-RBD interactions in determining spike phenotype

Kugathasan, R., Sukhova, K., Moshe, M., Kellam, P., & Barclay, W. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011545 · Cited by 16 · see citing works

What new COVID variants mean for schools is not yet clear

Lewis, D. (2021) · Nature · doi:10.1038/d41586-021-00139-3 · Cited by 15 · see citing works

A novel soluble ACE2 protein totally protects from lethal disease caused by SARS-CoV-2 infectionPreprint

Hassler, L., Wysocki, J. A., Gelarden, I. A., Τοματσίδου, Α., Gula, H., Nicoleascu, V., Randall, G. C., Henkin, J., Yeldandi, A. V., & BATLLE, D. C. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.12.435191 · Cited by 15 · see citing works

SARS-CoV-2 variants resist antibody neutralization and broaden host ACE2 usagePreprint

Wang, R., Zhang, Q., Ge, J., Ren, W., Zhang, R., Lan, J., Ju, B., Su, B., Yu, F., Chen, P., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.09.434497 · Cited by 14 · see citing works

David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors

Alfaleh, M. A., Zawawi, A., Alamri, S. S., & Hashem, A. M. (2022) · mAbs · doi:10.1080/19420862.2022.2057832 · Cited by 13 · see citing works

Polarity‐Dominated Stable N97 Respirators for Airborne Virus Capture Based on Nanofibrous Membranes

Wang, Q., Wei, Y., Li, W., Luo, X., Zhang, X., Di, J., Wang, G., & Yu, J. (2021) · Angewandte Chemie · doi:10.1002/ange.202108951 · Cited by 13 · see citing works

Intranasal soluble ACE2 improves survival and prevents brain SARS-CoV-2 infection

Hassler, L., Wysocki, J. A., Ahrendsen, J. T., Ye, M., Gelarden, I. A., Nicolaescu, V. I., Τοματσίδου, Α., Gula, H., Cianfarini, C. L., Khurram, N., et al. (2023) · Life Science Alliance · doi:10.26508/lsa.202301969 · Cited by 13 · see citing works

Emergence of SARS-CoV-2 B.1.1.7 Lineage at Outpatient Testing Site, Berlin, Germany, January–March 2021

van Loon, W., Rössig, H., Burock, S., Hofmann, J., Bernhard, J., Linzbach, E., Pettenkofer, D., Schönfeld, C., Gertler, M., Seybold, J., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2707.210845 · Cited by 11 · see citing works

High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses

Sims, J. J., Lian, S., Meggersee, R., Kasimsetty, A., & Wilson, J. M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0271359 · Cited by 11 · see citing works

Engineered ACE2 counteracts vaccine-evading SARS-CoV-2 Omicron variantPreprint

Ikemura, N., Taminishi, S., Inaba, T., Arimori, T., Motooka, D., Katoh, K., Kirita, Y., Higuchi, Y., Li, S., Suzuki, T., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.22.473804 · Cited by 11 · see citing works

Biomimetic Nanotechnology for SARS-CoV-2 Treatment

Li, S., Liu, X., Liu, G., & Liu, C. (2023) · Viruses · doi:10.3390/v15030596 · Cited by 10 · see citing works

Sequence basis for selectivity of ephrin-B2 ligand for Eph receptors and pathogenic henipavirus G glycoproteins

Narayanan, K. K., Amaya, M., Tsang, N., Yin, R., Jays, A., Broder, C. C., Shukla, D., & Procko, E. (2023) · Journal of Virology · doi:10.1128/jvi.00621-23 · Cited by 10 · see citing works

Lipid Nanoparticle-Based Inhibitors for SARS-CoV-2 Host Cell Infection

Yathindranath, V., Safa, N. A., Tomczyk, M. M., Dolinsky, V. W., & Miller, D. W. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s448005 · Cited by 10 · see citing works

Full-Length Computational Model of the SARS-CoV-2 Spike Protein and Its Implications for a Viral Membrane Fusion Mechanism

Nishima, W., & Kulik, M. (2021) · Viruses · doi:10.3390/v13061126 · Cited by 10 · see citing works

Real-time reverse transcription-polymerase chain reaction assay panel for the detection of severe acute respiratory syndrome coronavirus 2 and its variants

Lu, R., Zhao, L., Huang, B., Ye, F., Wang, W., & Tan, W. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001687 · Cited by 10 · see citing works

COVID-19 therapies: do we see substantial progress?

Matusewicz, L., Golec, M., Czogalla, A., Kuliczkowski, K., Konka, A., Zembala-John, J., & Sikorski, A. F. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00341-9 · Cited by 10 · see citing works

Modulation of the pharmacokinetics of soluble ACE2 decoy receptors through glycosylation

Skeeters, S. S., Bagale, K., Stepanyuk, G. A., Thieker, D. F., Aguhob, A., Chan, K. K., Dutzar, B., Shalygin, S. S., Shajahan, A., Xu, Y., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101301 · Cited by 9 · see citing works

Engineered soluble ACE2 receptor: Responding to change with change

Li, G., Qian, K., Zhang, S., Fu, W., Zhao, J. L., Lei, C., & Hu, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1084331 · Cited by 9 · see citing works

Machine Learning Guided Design of High-Affinity ACE2 Decoys for SARS-CoV-2 Neutralization

Chan, M. C., Chan, K. K., Procko, E., & Shukla, D. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.3c00469 · Cited by 9 · see citing works

From De Novo Design to Redesign: Harnessing Computational Protein Design for Understanding SARS-CoV-2 Molecular Mechanisms and Developing Therapeutics

Padhi, A. K., Kalita, P., Maurya, S., Poluri, K. M., & Tripathi, T. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.3c04542 · Cited by 8 · see citing works

Killing Two Birds with One Stone by Administration of Soluble ACE2: A Promising Strategy to Treat Both Cardiovascular Diseases and SARS-CoV-2 Infection

Feng, F., Chen, J., Zhao, J., Li, Y., Li, M., & Sun, C. (2021) · Viruses · doi:10.3390/v13112243 · Cited by 8 · see citing works

Development of a Peptide Sensor Derived from Human ACE2 for Fluorescence Polarization Assays of the SARS-CoV-2 Receptor Binding Domain

Okada, S., Muto, Y., Zhu, B., Ueda, H., & Nakamura, H. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.2c05818 · Cited by 7 · see citing works

Soluble Angiotensin-Converting Enzyme 2 Protein Improves Survival and Lowers Viral Titers in Lethal Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Type 2 Infection with the Delta Variant

Cianfarini, C. L., Hassler, L., Wysocki, J. A., Hassan, A., Nicolaescu, V. I., Elli, D., Gula, H., Ibrahim, A. M., Randall, G. C., Henkin, J., et al. (2024) · Cells · doi:10.3390/cells13030203 · Cited by 7 · see citing works

Atomistic Prediction of Structures, Conformational Ensembles and Binding Energetics for the SARS-CoV-2 Spike JN.1, KP.2 and KP.3 Variants Using AlphaFold2 and Molecular Dynamics Simulations: Mutational Profiling and Binding Free Energy Analysis Reveal Epistatic Hotspots of the ACE2 Affinity and Immune EscapePreprint

Raisinghani, N., Alshahrani, M., Gupta, G., & Verkhivker, G. M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.09.602810 · Cited by 7 · see citing works

Nitric oxide participates in sucrose–TOR signaling during meristem activation in Arabidopsis thaliana

Lando, A. P., Terrile, M. C., Marco, M. A. D., Rodríguez, M., & Martínez-Noël, G. M. A. (2024) · Planta · doi:10.1007/s00425-024-04542-8 · Cited by 6 · see citing works

Will Peptides Help to Stop COVID-19?

Krut’, V. G., Chuvpilo, S. A., Astrakhantseva, I. V., Kozlovskaya, L. I., Efimov, G. A., Kruglov, A., Drutskaya, M. S., & Nedospasov, S. A. (2022) · Biochemistry (Moscow) · doi:10.1134/s0006297922070021 · Cited by 6 · see citing works

Exploring Cannabinoids as Potential Inhibitors of SARS-CoV-2 Papain-like Protease: Insights from Computational Analysis and Molecular Dynamics Simulations

Holmes, J., Islam, S. M., & Milligan, K. A. (2024) · Viruses · doi:10.3390/v16060878 · Cited by 6 · see citing works

Metagenomic Analysis of the Species Composition and Seasonal Distribution of Marine Dinoflagellate Communities in Four Korean Coastal Regions

Hwang, J., Kang, H. W., Moon, S. J., Hyung, J.-H., Lee, E. S., & Park, J. (2022) · Microorganisms · doi:10.3390/microorganisms10071459 · Cited by 6 · see citing works

A SARS-CoV-2-neutralizing ACE2 decoy shows high affinity for N501Y and L452R variants

Tanaka, S., Olson, A., Nelson, G. A., Buzko, O. V., Higashide, W., Shin, A., Marco González, T., Taft, J. M., Patel, R., Buta, S., et al. (2021) · Topics in antiviral medicine

Broad Efficacy of a Computationally Designed ACE2 Decoy Against SARS-CoV-2 Omicron Variants and Related Viruses In Vitro and In Vivo

Havranek, B., Lindsey, G., Higuchi, Y., Itoh, Y., Suzuki, T., Okamoto, T., Hoshino, A., Procko, E., & Islam, S. M. (2023) · The Medicine Forum

An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants

Tanaka, S., Nelson, G., Olson, C. A., Buzko, O. V., Higashide, W., Shin, A., Gonzalez, M. R., Taft, J. D., Patel, R. S., Buta, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-91809-9 · Cited by 64 · see citing works

ACE2 decoy receptor generated by high-throughput saturation mutagenesis efficiently neutralizes SARS-CoV-2 and its prevalent variants

Wang, B., Zhao, J., Liu, S., Feng, J., Luo, Y., He, X., Wang, Y., Ge, F., Wang, J., Ye, B., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2079426 · Cited by 15 · see citing works

Engineered ACE2 decoy mitigates lung injury and death induced by SARS-CoV-2 variants

Zhang, L., Dutta, S., Xiong, S., Chan, M. C., Chan, K. K., Fan, T. M., Bailey, K. L., Lindeblad, M. O., Cooper, L. M., Rong, L., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-021-00965-6 · Cited by 85 · see citing works